Core Viewpoint - Aier Eye Hospital's stock price has experienced a slight decline, reflecting market fluctuations and investor sentiment towards the company’s strategic direction in the eye care industry [1] Company Overview - Aier Eye Hospital is a leading ophthalmology medical chain in China, providing services that include eye diagnosis, surgery, and optical services [1] - The company has adopted a growth strategy that combines self-built facilities and acquisitions, expanding its medical institutions globally [1] Management Strategy - The management has emphasized a cautious approach to acquisitions, highlighting the need for a robust quality control and management system before pursuing new opportunities [1] - Director Wu Shijun stated that it is essential to avoid blind following of market trends and to maintain a safety margin in their strategies [1] Financial Performance - As of August 6, 2025, Aier Eye Hospital's stock price was reported at 12.82 yuan, with a trading volume of 535,300 hands and a total transaction amount of 686 million yuan [1] - The company held its second extraordinary general meeting in 2025, which approved the completion of certain fundraising projects [1] - As of March 31, 2025, the total number of shareholders was 347,300 [1] Market Activity - On August 6, 2025, the net outflow of main funds was 82.86 million yuan, with a cumulative net outflow of 459 million yuan over the past five days [1]

21世纪经济报道记者 申俊涵 北京报道 7月29日，"并购破局：存量时代的投退博弈"闭门研讨会在北京成功举办。现场，来自政府投资基金、 产业资本、GP/LP及中介机构的50余位嘉宾齐聚一堂，围绕并购市场的政策趋势、机遇与挑战，并购投 资的交易实践等话题，展开精彩分享和深度讨论。 会上，爱尔眼科董事、副总经理兼董事会秘书吴士君分享了爱尔眼科的并购实践经验。据了解，爱尔眼 科从2009年前后开始做并购，公司现有医疗机构中约半数是收购整合而来。同时，公司的并购标的分布 广泛，不仅涉及国内近30个省区，还包括在海外进行国际化并购。 如何对标的项目进行估值？据了解，市场中有市盈率、市净率、市销率、参考样本定价等各种各样的估 值方法。爱尔眼科会把现有的方法综合运用，再结合项目的具体情况，形成对项目的合理估值。值得注 意的是，在财务性收购中，主要关注项目本身的估值。但在战略性收购中，更要考虑到收购后对标的内 涵价值的增值成长。 吴士君回忆了爱尔眼科第一次做收购的情形：当时，那家医疗机构由两位著名的眼科医生创办，机构的 年收入为五六百万，并且连续多年增长不大。这笔收购从市盈率角度看估值并不低，最终，爱尔眼科还 是以双方满意的 ...

截至2025年8月5日收盘，爱尔眼科股价报12.86元，较前一交易日下跌0.02元，跌幅0.16%。当日成交额 达7.20亿元，成交量559755手，振幅1.40%。 爱尔眼科属于医疗服务板块，是国内专业眼科连锁医疗机构。公司主要从事各类眼科疾病诊疗、手术服 务与医学验光配镜等业务。 公司最新公告显示，2025年第二次临时股东大会审议通过了关于部分募投项目结项并将节余募集资金永 久补充流动资金的议案。此外，公司披露截至2025年3月31日股东总数为347329户。 资金流向方面，8月5日主力资金净流出9228.39万元，近五个交易日累计净流出4.19亿元。 风险提示：股市有风险，投资需谨慎。 来源：金融界 ...

Group 1 - The company, Aier Eye Hospital, disclosed that as of March 31, 2025, the total number of shareholders is 347,329 [2]

（文章来源：证券日报） 证券日报网讯 8月5日晚间，爱尔眼科发布公告称，公司2025年第二次临时股东大会审议通过了《关于 部分募投项目结项并将节余募集资金永久补充流动资金的议案》。 ...

证券代码：300015 股票简称：爱尔眼科 公告编号：2025-055 爱尔眼科医院集团股份有限公司 2025 年第二次临时股东大会决议公告 本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形。 2、本次股东大会未涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 爱尔眼科医院集团股份有限公司（以下简称"公司"）2025 年第二次临时 股东大会采用现场表决与网络投票相结合的方式召开。其中，通过深圳证券交易 所交易系统进行网络投票的时间为：2025 年 8 月 5 日 9:15 至 9:25、9:30 至 11:30， 13:00 至 15:00；通过深圳证券交易所互联网投票系统投票的具体时间为：2025 年 8 月 5 日 9:15 至 15:00 期间的任意时间；现场会议于 2025 年 8 月 5 日 14:30 在长沙市芙蓉南路一段 188 号爱尔大厦 B1 层国际会议厅召开。本次股东大会由 公司董事会召集，副董事长李力先生主持，公司董事、监事、高级管理人员、律 师等相关人士出席了本次会议。会议的召集、召开 ...

湖南启元律师事务所 关于爱尔眼科医院集团股份有限公司 2025年第二次临时股东大会的 法律意见书 二零二五年八月五日 致：爱尔眼科医院集团股份有限公司 湖南启元律师事务所（以下简称"本所"）接受爱尔眼科医院集团股份有限 公司（以下简称"公司"）的委托，指派本所律师出席了公司 2025 年第二次临时 股东大会（以下简称"本次股东大会"），对本次股东大会的召集和召开程序、 出席会议人员及召集人的资格、表决程序和表决结果的合法有效性进行律师见证， 并发表本法律意见。 （二）本所律师遵循了勤勉尽责和诚实信用原则，严格履行了法定职责，对 本法律意见书出具日以前已经发生或者存在的事实进行了充分的核查验证，保证 本法律意见书所认定的事实真实、准确、完整，所发表的结论性意见合法、准 确，不存在虚假记载、误导性陈述或者重大遗漏。 （三）本所律师未授权任何单位或个人对本法律意见书作任何解释或说明。 为发表本法律意见，本所律师依法查验了公司提供的下列资料： 1、刊登在深圳证券交易所网站（http://www.szse.cn/）的与本次股东大会有 关的通知等公告事项； 2、出席会议的股东或其代理人的身份证明文件、授权委托书等； 本所 ...

Core Insights - The healthcare ETF, Taikang (159760), has shown a slight increase of 0.46%, tracking the National Public Health and Healthcare Index (980016), which rose by 0.48% [1] - A new pricing mechanism for newly launched drugs has been established by the National Healthcare Security Administration, allowing high-level innovative drugs a five-year price stability period, which is expected to reverse the trend of price drops upon market entry [1] - Innovative drugs like Zebutinib from BeiGene and the dual-antibody drug from Baillie Tianheng are anticipated to drive significant revenue growth in the coming years [1][2] Industry Developments - The index constituents are experiencing a technological breakthrough, with companies like Kangfang Bio and Eli Lilly making significant advancements in drug development [2] - The AI+mRNA platform developed by CloudTop has achieved full-chain coverage from antigen design to industrial production, indicating a shift in innovative drug development paradigms [3] - The index includes companies that are directly benefiting from healthcare payment reforms and supportive policies for innovative drugs, with over 80% of the constituents poised to gain from these changes [4] Financial Performance - As of June 30, 2025, the top ten weighted stocks in the National Public Health and Healthcare Index accounted for 51.67% of the index, with companies like WuXi AppTec and Hengrui Medicine leading the way [5] - Hengrui Medicine's R&D investment ratio reached 28% in the first half of 2025, with a 50% year-on-year increase in the number of new drug approvals, indicating strong growth potential [4] Market Outlook - The healthcare ETF is expected to continue leading in the structural market of the healthcare industry, driven by the expansion of commercial insurance innovative drug catalogs and accelerated approvals for AI medical devices [4] - The index reflects the performance of listed companies in the public health and healthcare sector, focusing on prevention, testing, and treatment areas with significant potential for AI technology applications [4]

Group 1 - The core viewpoint is that the liquidity and fundamentals of the Chinese healthcare industry continue to improve, maintaining a positive outlook for the healthcare sector [1] - The report indicates that the weak U.S. employment data may lead to heightened expectations for monetary easing in the second half of the year, suggesting an improved outlook for the industry [1] - The report highlights that the industry fundamentals are recovering, with a month-on-month increase in hospital prescription volumes in July, and significant profit growth expected in the third quarter due to the release of more innovative drugs [1] Group 2 - The company prefers leading large pharmaceutical firms and suggests avoiding companies overly reliant on biosimilars in the short term [2] - Selected stocks include: CSPC Pharmaceutical Group (01093), Sinopharm Group (01099), Hansoh Pharmaceutical (03692), and others [2] - The report emphasizes that the uncertainty in U.S. Treasury yields may prompt a reallocation of funds, further improving the liquidity of innovative drug assets [1]

里昂指出，行业基本面持续复苏，7月院内处方量环比提升，随着更多创新药放量，第三季行业盈利有 望实现显著增长，加上美债不确定性可能促使资金重新配置，进一步改善创新药资产流动性，相信行业 拐点已过，未来将迎来盈喜等正面催化剂。 该行偏好领先大型药厂，短期而言避开过度依赖生物仿制药的公司。该行选股包括石药集团(01093)、 新诺威(300765.SZ)、翰森制药(03692)、爱尔眼科(300015.SZ)、恒瑞医药(01276,600276.SH)、康方生物 (09926)、中生制药(01177)、国药控股(01099)、康哲药业(00867)、大参林(603233.SH)、华东医药 (000963.SZ)、泰格医药(03347)及药明康德(02359)。 智通财经APP获悉，里昂发布研报称，中国医疗健康行业流动性及基本面持续改善，维持对医疗健康板 块正面看法，指出美国就业数据疲软或市场对下半年货币宽松预期急升温，预示着行业下半年改善前 景，相信特朗普再提最惠国药品定价政策及安徽启动生物类似药集中采购，对行业影响则相对有限。 ...